Belantamab Mafodotin Combo Shows PFS Improvement in R/R Multiple Myeloma

被引：0
|
作者：
不详
机构：
来源：
ONCOLOGY-NEW YORK | 2024年 / 38卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：44
相关论文
共 50 条
  • [41] EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma
    Tzogani, Kyriaki
    Penttil, Karri
    Lahteenvuo, Johanna
    Lapvetelainen, Tuomo
    Lopez Anglada, Lucia
    Prieto, Carolina
    Garcia-Ochoa, Blanca
    Enzmann, Harald
    Gisselbrecht, Christian
    Delgado, Julio
    Pignatti, Francesco
    ONCOLOGIST, 2021, 26 (01): : 70 - 76
  • [42] Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myeloma
    Abeykoon, Jithma P.
    Vaxman, Julia
    Patel, Sanjay V.
    Kumar, Shaji
    Malave, Gabriella C.
    Young, Kimberly S.
    Ailawadhi, Sikander
    Larsen, Jeremy T.
    Dispenzieri, Angela
    Muchtar, Eli
    Gonsalves, Wilson I.
    Kourelis, Taxiarchis
    Leung, Nelson
    Warsame, Rahma
    Go, Ronald S.
    Bergsagel, Leif
    Lacy, Martha Q.
    Rajkumar, S. Vincent
    Gertz, Morie A.
    Kapoor, Prashant
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 199 (01) : 95 - 99
  • [43] A real-world experience of efficacy and safety of belantamab mafodotin in relapsed refractory multiple myeloma
    Dileo, Rachel
    Mewawalla, Prerna
    Babu, Kalaivani
    Yin, Yue
    Strouse, Christopher
    Chen, Ethan
    Shaikh, Hira
    Davis, James A.
    Green, Kimberly M.
    Alkharabsheh, Omar
    Rashid, Aliya
    Pokhrel, Bidushi
    Ahmed, Nausheen
    Abdallah, Al-Ola
    Hashmi, Hamza
    BLOOD CANCER JOURNAL, 2025, 15 (01):
  • [44] Profile and Management of Toxicity of Selinexor and Belantamab Mafodotin for the Treatment of Triple Class Refractory Multiple Myeloma
    Neupane, Karun
    Wahab, Ahsan
    Masood, Adeel
    Faraz, Tehniat
    Bahram, Saman
    Ehsan, Hamid
    Hannan, Abdul
    Anwer, Faiz
    JOURNAL OF BLOOD MEDICINE, 2021, 12 : 529 - 550
  • [45] Auftreten von kornealen mikrozystoiden Veränderungen unter Belantamab-Mafodotin-Gabe beim multiplen MyelomOccurrence of corneal microcystoid alterations under administration of belantamab mafodotin for multiple myeloma
    Julian Zimmermann
    E. Esser
    N. Eter
    P. Schütt
    C. E. Uhlig
    Die Ophthalmologie, 2023, 120 : 747 - 750
  • [46] Effectiveness and Safety of Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma in RealLife Setting: The ALFA Study
    Roussel, Murielle
    Texier, Nathalie
    Germain, Raphael
    Sapra, Sandhya
    Paka, Prani
    Kerbouche, Naima
    Colin, Xavier
    Leleu, Xavier
    BLOOD, 2022, 140 : 4261 - 4263
  • [47] Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor
    Joseph, Nisha S.
    Tai, Yu-Tzu
    Anderson, Kenneth C.
    Lonial, Sagar
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2021, 13 : 169 - 180
  • [48] Real-world analysis of belantamab mafodotin (belamaf): Care patterns in relapsed/refractory multiple myeloma
    Patel, Mihir
    Locke, Susan C.
    Falvey, Caroline
    Troy, Jesse D.
    Herring, Kris W.
    Bolgioni-Smith, Amanda
    Doherty, Allison
    Elcock, Cherie Howard
    Iadeluca, Laura L.
    LeBlanc, Thomas William
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [49] Phase I/II Study of Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone (BelCyd) in Relapsed/Refractory Multiple Myeloma
    Badros, Ashraf Z.
    Nash, Thea
    Lawrance, Christopher
    Tittle, Brandon
    Philip, Sunita
    Sunshine, Sarah
    Munir, Wuqaas
    Fan, Xiaoxuan
    Ide, Christina
    Atanackovic, Djordje
    BLOOD, 2023, 142
  • [50] Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)
    Lonial, Sagar
    Nooka, Ajay K.
    Thulasi, Praneetha
    Badros, Ashraf Z.
    Jeng, Bennie H.
    Callander, Natalie S.
    Potter, Heather A.
    Sborov, Douglas
    Zaugg, Brian E.
    Popat, Rakesh
    Degli Esposti, Simona
    Byrne, Julie
    Opalinska, Joanna
    Baron, January
    Piontek, Trisha
    Gupta, Ira
    Dana, Reza
    Farooq, Asim V.
    Colby, Kathryn
    Jakubowiak, Andrzej
    BLOOD CANCER JOURNAL, 2021, 11 (05)
12345